Last reviewed · How we verify

Hydroquinone Topical

University of California, Davis · FDA-approved active Small molecule Quality 5/100

Hydroquinone Topical is a Small molecule drug developed by University of California, Davis. It is currently FDA-approved. Also known as: Hydroquinone.

Hydroquinone Topical, developed by the University of California, Davis, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameHydroquinone Topical
Also known asHydroquinone
SponsorUniversity of California, Davis
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hydroquinone Topical

What is Hydroquinone Topical?

Hydroquinone Topical is a Small molecule drug developed by University of California, Davis.

Who makes Hydroquinone Topical?

Hydroquinone Topical is developed and marketed by University of California, Davis (see full University of California, Davis pipeline at /company/university-of-california-davis).

Is Hydroquinone Topical also known as anything else?

Hydroquinone Topical is also known as Hydroquinone.

What development phase is Hydroquinone Topical in?

Hydroquinone Topical is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing